Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (209)

« Back to Publications

The use of fenofibrate in diabetic retinopathy: Narrative review.

Dissanayake HA. et al, (2025), J Diabetes Complications, 39

Cost-effectiveness of fenofibrate versus standard care for reducing the progression of diabetic retinopathy: An economic evaluation based on data from the LENS trial.

Scotland G. et al, (2025), Diabet Med, 42

Association of Daily Steps with Incident Nonalcoholic Fatty Liver Disease: Evidence from the UK Biobank Cohort.

Fulda ES. et al, (2025), Med Sci Sports Exerc, 57, 1905 - 1913

Using a Markov Model and Real-World Evidence to Identify the Most Cost-Effective Cholesterol Treatment Escalation Threshold for the Secondary Prevention of Cardiovascular Disease.

Mariani A. et al, (2025), Appl Health Econ Health Policy, 23, 869 - 883

Fenofibrate and progression of retinopathy in adults with diabetes: the randomised placebo-controlled LENS trial

PREISS D. et al, (2025), NIHR Journals Library

Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.

Zhou J. et al, (2025), EClinicalMedicine, 85

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.

Mayne KJ. et al, (2025), Nephrol Dial Transplant, 40, 720 - 730

Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.

EMPA-KIDNEY Collaborative Group . et al, (2025), N Engl J Med, 392, 777 - 787

Quality of care for secondary cardiovascular disease prevention in 2009-2017: population-wide cohort study of antiplatelet therapy use in Scotland.

Thalmann I. et al, (2024), BMJ Qual Saf, 33, 716 - 725

Design, recruitment and baseline characteristics of the LENS trial.

LENS Collaborative Group ., (2024), Diabet Med, 41

Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.

Mayne KJ. et al, (2024), Clin J Am Soc Nephrol, 19, 1119 - 1129

Patient and public involvement and engagement in the ASCEND PLUS trial: reflections from the design of a streamlined and decentralised clinical trial.

El-Nayir M. et al, (2024), Trials, 25

Towards an understanding of the ethics of electronic consent in clinical trials.

Sahan K. et al, (2024), Trials, 25

Effect of Fenofibrate on Progression of Diabetic Retinopathy.

Preiss D. et al, (2024), NEJM Evid, 3

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial.

Mayne KJ. et al, (2024), Clin J Am Soc Nephrol, 19, 1119 - 1129

Load More

1
2
3
4
5
6
7
...
»